ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Recombinant Human Coagulation VIIa Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-1C11632
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Recombinant Human Coagulation VIIa Market Research Report 2022
BUY CHAPTERS

Global Recombinant Human Coagulation VIIa Market Research Report 2025

Code: QYRE-Auto-1C11632
Report
March 2025
Pages:67
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Generium

Recombinant Human Coagulation VIIa Market Size

The global market for Recombinant Human Coagulation VIIa was valued at US$ 1251 million in the year 2024 and is projected to reach a revised size of US$ 1608 million by 2031, growing at a CAGR of 3.7% during the forecast period.

Recombinant Human Coagulation VIIa Market

Recombinant Human Coagulation VIIa Market

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for:
Treatment of bleeding episodes and perioperative management in adults and children with Hemophilia or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
Treatment of bleeding episodes and perioperative management in adults with acquired haemophilia.
Drivers of the Recombinant Human Coagulation Factor VIIa (rFVIIa) Market:
Rising Prevalence of Hemophilia and Bleeding Disorders: Recombinant Factor VIIa is primarily used in treating hemophilia, especially in patients with inhibitors to Factor VIII or IX. The growing global incidence of hemophilia and other bleeding disorders is a major driver of market demand.
Advancements in Recombinant Technology: Ongoing improvements in biotechnology have led to the development of safer and more effective recombinant coagulation products. These advancements reduce the risk of bloodborne pathogen transmission, increasing their adoption over plasma-derived alternatives.
Increased Use in Trauma and Surgery: Recombinant Factor VIIa is also used in managing severe bleeding during trauma and surgical procedures, further expanding its clinical applications and boosting demand, particularly in emergency care settings.
Rising Adoption in Off-Label Uses: While its primary indication is for hemophilia, rFVIIa is increasingly being used off-label to manage uncontrolled bleeding in non-hemophiliac patients, particularly in critical care and trauma settings. This broadens its potential market.
Favorable Reimbursement Policies in Developed Regions: In regions like North America and Europe, the availability of comprehensive insurance and reimbursement for advanced therapies like rFVIIa makes these treatments more accessible to patients, supporting market growth.
Challenges of the Recombinant Human Coagulation Factor VIIa (rFVIIa) Market:
High Cost of Treatment: Recombinant Factor VIIa therapy is expensive, which can limit access, especially in low-income countries and regions without robust healthcare funding or insurance coverage.
Potential for Off-Label Use Concerns: Despite its increasing use in off-label applications, concerns about the safety and efficacy of rFVIIa in non-hemophilia patients have led to caution in its broader application. Regulatory scrutiny on off-label use may impact market expansion.
Limited Awareness and Access in Developing Regions: In many developing countries, awareness of recombinant therapies for hemophilia is limited, and access to advanced treatments is constrained by inadequate healthcare infrastructure and funding.
Competition from Alternative Therapies: Emerging gene therapies, extended half-life clotting factors, and other innovative treatments for hemophilia may compete with or reduce the demand for rFVIIa in the future. These newer therapies promise more long-term efficacy or convenience.
Regulatory Challenges: The stringent regulatory approval process for biologics, along with the ongoing need for post-market surveillance, can slow down the introduction of new products or indications, impacting the pace of market growth.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Human Coagulation VIIa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Coagulation VIIa.
The Recombinant Human Coagulation VIIa market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Human Coagulation VIIa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Coagulation VIIa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Recombinant Human Coagulation VIIa Market Report

Report Metric Details
Report Name Recombinant Human Coagulation VIIa Market
Accounted market size in year US$ 1251 million
Forecasted market size in 2031 US$ 1608 million
CAGR 3.7%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Recombinant Human Coagulation VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Recombinant Human Coagulation VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Recombinant Human Coagulation VIIa Market growing?

Ans: The Recombinant Human Coagulation VIIa Market witnessing a CAGR of 3.7% during the forecast period 2025-2031.

What is the Recombinant Human Coagulation VIIa Market size in 2031?

Ans: The Recombinant Human Coagulation VIIa Market size in 2031 will be US$ 1608 million.

What is the market share of major companies in Recombinant Human Coagulation VIIa Market?

Ans: The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%.

What is the Novo Nordisk share in Recombinant Human Coagulation VIIa Market?

Ans: The largest manufacturer is Novo Nordisk, with a market share of more than 95%.

What is the Recombinant Human Coagulation VIIa Market share by region?

Ans: North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

Who are the main players in the Recombinant Human Coagulation VIIa Market report?

Ans: The main players in the Recombinant Human Coagulation VIIa Market are Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM

What are the Application segmentation covered in the Recombinant Human Coagulation VIIa Market report?

Ans: The Applications covered in the Recombinant Human Coagulation VIIa Market report are Congenital Hemophilia, Acquired Hemophilia, Others

What are the Type segmentation covered in the Recombinant Human Coagulation VIIa Market report?

Ans: The Types covered in the Recombinant Human Coagulation VIIa Market report are Prefilled Syringe, Vial

Recommended Reports

Coagulation & Hemostasis

Hemophilia & Genetics

Recombinant & Plasma Products

1 Recombinant Human Coagulation VIIa Market Overview
1.1 Product Definition
1.2 Recombinant Human Coagulation VIIa by Type
1.2.1 Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2024 VS 2031)
1.2.2 Prefilled Syringe
1.2.3 Vial
1.3 Recombinant Human Coagulation VIIa by Application
1.3.1 Global Recombinant Human Coagulation VIIa Market Value by Application (2024 VS 2031)
1.3.2 Congenital Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Others
1.4 Global Recombinant Human Coagulation VIIa Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Coagulation VIIa Revenue 2020-2031
1.4.2 Global Recombinant Human Coagulation VIIa Sales 2020-2031
1.4.3 Global Recombinant Human Coagulation VIIa Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Recombinant Human Coagulation VIIa Market Competition by Manufacturers
2.1 Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2020-2025)
2.2 Global Recombinant Human Coagulation VIIa Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Recombinant Human Coagulation VIIa Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Recombinant Human Coagulation VIIa, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Type & Application
2.7 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Date of Enter into This Industry
2.8 Global Recombinant Human Coagulation VIIa Market Competitive Situation and Trends
2.8.1 Global Recombinant Human Coagulation VIIa Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Recombinant Human Coagulation VIIa Players Market Share by Revenue
2.8.3 Global Recombinant Human Coagulation VIIa Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Recombinant Human Coagulation VIIa Market Scenario by Region
3.1 Global Recombinant Human Coagulation VIIa Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Recombinant Human Coagulation VIIa Sales by Region: 2020-2031
3.2.1 Global Recombinant Human Coagulation VIIa Sales by Region: 2020-2025
3.2.2 Global Recombinant Human Coagulation VIIa Sales by Region: 2026-2031
3.3 Global Recombinant Human Coagulation VIIa Revenue by Region: 2020-2031
3.3.1 Global Recombinant Human Coagulation VIIa Revenue by Region: 2020-2025
3.3.2 Global Recombinant Human Coagulation VIIa Revenue by Region: 2026-2031
3.4 North America Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.4.1 North America Recombinant Human Coagulation VIIa Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Recombinant Human Coagulation VIIa Sales by Country (2020-2031)
3.4.3 North America Recombinant Human Coagulation VIIa Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Coagulation VIIa Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Recombinant Human Coagulation VIIa Sales by Country (2020-2031)
3.5.3 Europe Recombinant Human Coagulation VIIa Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Coagulation VIIa Market Facts & Figures by Region
3.6.1 Asia Pacific Recombinant Human Coagulation VIIa Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (2020-2031)
3.6.3 Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Coagulation VIIa Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Recombinant Human Coagulation VIIa Sales by Country (2020-2031)
3.7.3 Latin America Recombinant Human Coagulation VIIa Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Coagulation VIIa Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (2020-2031)
3.8.3 Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Human Coagulation VIIa Sales by Type (2020-2031)
4.1.1 Global Recombinant Human Coagulation VIIa Sales by Type (2020-2025)
4.1.2 Global Recombinant Human Coagulation VIIa Sales by Type (2026-2031)
4.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2020-2031)
4.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2020-2031)
4.2.1 Global Recombinant Human Coagulation VIIa Revenue by Type (2020-2025)
4.2.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2026-2031)
4.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2020-2031)
4.3 Global Recombinant Human Coagulation VIIa Price by Type (2020-2031)
5 Segment by Application
5.1 Global Recombinant Human Coagulation VIIa Sales by Application (2020-2031)
5.1.1 Global Recombinant Human Coagulation VIIa Sales by Application (2020-2025)
5.1.2 Global Recombinant Human Coagulation VIIa Sales by Application (2026-2031)
5.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2020-2031)
5.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2020-2031)
5.2.1 Global Recombinant Human Coagulation VIIa Revenue by Application (2020-2025)
5.2.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2026-2031)
5.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2020-2031)
5.3 Global Recombinant Human Coagulation VIIa Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novo Nordisk Recombinant Human Coagulation VIIa Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA HEMA Biologics
6.2.1 LFB SA HEMA Biologics Company Information
6.2.2 LFB SA HEMA Biologics Description and Business Overview
6.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2020-2025)
6.2.4 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product Portfolio
6.2.5 LFB SA HEMA Biologics Recent Developments/Updates
6.3 AryoGen Pharmed
6.3.1 AryoGen Pharmed Company Information
6.3.2 AryoGen Pharmed Description and Business Overview
6.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AryoGen Pharmed Recombinant Human Coagulation VIIa Product Portfolio
6.3.5 AryoGen Pharmed Recent Developments/Updates
6.4 GENERIUM
6.4.1 GENERIUM Company Information
6.4.2 GENERIUM Description and Business Overview
6.4.3 GENERIUM Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GENERIUM Recombinant Human Coagulation VIIa Product Portfolio
6.4.5 GENERIUM Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Coagulation VIIa Industry Chain Analysis
7.2 Recombinant Human Coagulation VIIa Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Coagulation VIIa Production Mode & Process Analysis
7.4 Recombinant Human Coagulation VIIa Sales and Marketing
7.4.1 Recombinant Human Coagulation VIIa Sales Channels
7.4.2 Recombinant Human Coagulation VIIa Distributors
7.5 Recombinant Human Coagulation VIIa Customer Analysis
8 Recombinant Human Coagulation VIIa Market Dynamics
8.1 Recombinant Human Coagulation VIIa Industry Trends
8.2 Recombinant Human Coagulation VIIa Market Drivers
8.3 Recombinant Human Coagulation VIIa Market Challenges
8.4 Recombinant Human Coagulation VIIa Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Generium
List of Tables
 Table 1. Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Recombinant Human Coagulation VIIa Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Recombinant Human Coagulation VIIa Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Recombinant Human Coagulation VIIa Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Recombinant Human Coagulation VIIa Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Recombinant Human Coagulation VIIa Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Recombinant Human Coagulation VIIa, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Type & Application
 Table 12. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Recombinant Human Coagulation VIIa by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Coagulation VIIa as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Recombinant Human Coagulation VIIa Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Recombinant Human Coagulation VIIa Sales by Region (2020-2025) & (K Units)
 Table 18. Global Recombinant Human Coagulation VIIa Sales Market Share by Region (2020-2025)
 Table 19. Global Recombinant Human Coagulation VIIa Sales by Region (2026-2031) & (K Units)
 Table 20. Global Recombinant Human Coagulation VIIa Sales Market Share by Region (2026-2031)
 Table 21. Global Recombinant Human Coagulation VIIa Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Recombinant Human Coagulation VIIa Revenue Market Share by Region (2020-2025)
 Table 23. Global Recombinant Human Coagulation VIIa Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Recombinant Human Coagulation VIIa Revenue Market Share by Region (2026-2031)
 Table 25. North America Recombinant Human Coagulation VIIa Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Recombinant Human Coagulation VIIa Sales by Country (2020-2025) & (K Units)
 Table 27. North America Recombinant Human Coagulation VIIa Sales by Country (2026-2031) & (K Units)
 Table 28. North America Recombinant Human Coagulation VIIa Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Recombinant Human Coagulation VIIa Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Recombinant Human Coagulation VIIa Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Recombinant Human Coagulation VIIa Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Recombinant Human Coagulation VIIa Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Recombinant Human Coagulation VIIa Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Recombinant Human Coagulation VIIa Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Recombinant Human Coagulation VIIa Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Recombinant Human Coagulation VIIa Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Recombinant Human Coagulation VIIa Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Recombinant Human Coagulation VIIa Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Recombinant Human Coagulation VIIa Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Recombinant Human Coagulation VIIa Sales (K Units) by Type (2020-2025)
 Table 51. Global Recombinant Human Coagulation VIIa Sales (K Units) by Type (2026-2031)
 Table 52. Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2020-2025)
 Table 53. Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2026-2031)
 Table 54. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2020-2025)
 Table 57. Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2026-2031)
 Table 58. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Recombinant Human Coagulation VIIa Sales (K Units) by Application (2020-2025)
 Table 61. Global Recombinant Human Coagulation VIIa Sales (K Units) by Application (2026-2031)
 Table 62. Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2020-2025)
 Table 63. Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2026-2031)
 Table 64. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2020-2025)
 Table 67. Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2026-2031)
 Table 68. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2026-2031)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Novo Nordisk Recombinant Human Coagulation VIIa Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. LFB SA HEMA Biologics Company Information
 Table 76. LFB SA HEMA Biologics Description and Business Overview
 Table 77. LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product
 Table 79. LFB SA HEMA Biologics Recent Developments/Updates
 Table 80. AryoGen Pharmed Company Information
 Table 81. AryoGen Pharmed Description and Business Overview
 Table 82. AryoGen Pharmed Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. AryoGen Pharmed Recombinant Human Coagulation VIIa Product
 Table 84. AryoGen Pharmed Recent Developments/Updates
 Table 85. GENERIUM Company Information
 Table 86. GENERIUM Description and Business Overview
 Table 87. GENERIUM Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. GENERIUM Recombinant Human Coagulation VIIa Product
 Table 89. GENERIUM Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Recombinant Human Coagulation VIIa Distributors List
 Table 93. Recombinant Human Coagulation VIIa Customers List
 Table 94. Recombinant Human Coagulation VIIa Market Trends
 Table 95. Recombinant Human Coagulation VIIa Market Drivers
 Table 96. Recombinant Human Coagulation VIIa Market Challenges
 Table 97. Recombinant Human Coagulation VIIa Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Recombinant Human Coagulation VIIa
 Figure 2. Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Recombinant Human Coagulation VIIa Market Share by Type: 2024 & 2031
 Figure 4. Prefilled Syringe Product Picture
 Figure 5. Vial Product Picture
 Figure 6. Global Recombinant Human Coagulation VIIa Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Recombinant Human Coagulation VIIa Market Share by Application: 2024 & 2031
 Figure 8. Congenital Hemophilia
 Figure 9. Acquired Hemophilia
 Figure 10. Others
 Figure 11. Global Recombinant Human Coagulation VIIa Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Recombinant Human Coagulation VIIa Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Recombinant Human Coagulation VIIa Sales (2020-2031) & (K Units)
 Figure 14. Global Recombinant Human Coagulation VIIa Average Price (US$/Unit) & (2020-2031)
 Figure 15. Recombinant Human Coagulation VIIa Report Years Considered
 Figure 16. Recombinant Human Coagulation VIIa Sales Share by Manufacturers in 2024
 Figure 17. Global Recombinant Human Coagulation VIIa Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Recombinant Human Coagulation VIIa Players: Market Share by Revenue in Recombinant Human Coagulation VIIa in 2024
 Figure 19. Recombinant Human Coagulation VIIa Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Recombinant Human Coagulation VIIa Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Recombinant Human Coagulation VIIa Sales Market Share by Country (2020-2031)
 Figure 22. North America Recombinant Human Coagulation VIIa Revenue Market Share by Country (2020-2031)
 Figure 23. United States Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Recombinant Human Coagulation VIIa Sales Market Share by Country (2020-2031)
 Figure 26. Europe Recombinant Human Coagulation VIIa Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Recombinant Human Coagulation VIIa Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Recombinant Human Coagulation VIIa Revenue Market Share by Region (2020-2031)
 Figure 34. China Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Recombinant Human Coagulation VIIa Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Recombinant Human Coagulation VIIa Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Recombinant Human Coagulation VIIa Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Recombinant Human Coagulation VIIa Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Recombinant Human Coagulation VIIa Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Recombinant Human Coagulation VIIa by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Recombinant Human Coagulation VIIa by Type (2020-2031)
 Figure 55. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Recombinant Human Coagulation VIIa by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Recombinant Human Coagulation VIIa by Application (2020-2031)
 Figure 58. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2020-2031)
 Figure 59. Recombinant Human Coagulation VIIa Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Recombinant Human Thrombin for Surgical Hemostasis Market Research Report 2024
Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Eptacog Alfa Recombinant Human Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Activated Coagulation Factor VII Market Research Report 2025
Global Human Coagulation Factor VII Market Insights Forecast to 2030
Global Eptacog Alfa rFVIIa Market Research Report 2025
Global Recombinant Coagulation Factors Market Insights Forecast to 2030
Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Topical Recombinant Human Thrombin Market Research Report 2024
Global Recombinant Coagulation Factor IX Market Research Report 2025
Global Recombinant Coagulation Factor Concentrate Market Research Report 2024
Global Recombinant Human Coagulation Factor VIII for Injection Market Research Report 2024
Biological Hemostatic Material Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Human Thrombin Protein Market Research Report 2024
Plasma derived Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Topical Recombinant Thrombin Market Research Report 2024
Global Human Coagulation Factor IX Market Research Report 2024
Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions